June 11, 2020 -- Grifols will start production of anti-SARS-CoV-2 hyperimmune immunoglobulin with specific antibodies using plasma from patients who have recovered from COVID-19.
The production of the COVID-19 immunotherapy is part of a collaboration with the U.S. Food and Drug Administration, the National Institutes of Health, and the Biomedical Advanced Research Development Authority, among others. The drug will be produced in the company's Clayton, NC, facility which is specifically designed to process specialty immunoglobulins.
Immunoglobulins are plasma proteins that act like antibodies as part of the body's defense system. They have a broad scope of action including immunomodulatory effects. Immunoglobulins are used to treat autoimmune diseases and neurological conditions.
The first doses are expected to be available in July 2020 as part of a clinical trial in partnership with healthcare agencies, according to the company.
Copyright © 2020 scienceboard.net